Sort
172,184 grants matching “inflammation”
Development of a dry powder inhalation product against Respiratory Syncytial Virus based on an endogenous anionic pulmonary surfactant lipid
$1,000,000Ajay Gupta · Celestial Therapeutics Inc. · R44 · FY2025 · AI
A Novel Immunologically Enhanced Probiotic for Treating Rheumatoid Arthritis
$1,000,000Gary Fanger · Rise Therapeutics, Llc · R44 · FY2022 · AI
Bridging Interventional Development Gaps (BrIDGs)
$1,000,000Leidos Biomedical Research, Inc. · N01 · FY2012 · CA
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis
$1,000,000Joe G. N. Garcia · Aqualung Therapeutics Corp. · R42 · FY2021 · HL
CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE
$1,000,000University Of North Carolina Chapel Hill · P30 · FY2004 · DK
CENTER FOR GASTROINTESTINAL BIOLOGY AND DISEASE
$1,000,000University Of North Carolina Chapel Hill · P30 · FY2002 · DK
Universal Influenza A/B Vaccine
$1,000,000Kenneth C Bagley · Orlance, Inc. · R44 · FY2022 · AI
CENTER FOR DIGESTIVE AND LIVER DISEASES
$1,000,000University Of Pennsylvania · P30 · FY2001 · DK
Treatment of Inflammatory Complications of Respiratory Infection
$1,000,000Michael William Lark · Respana Therapeutics, Inc. · R42 · FY2024 · AI
SAC-COVID: An FDA-approved Phase III clinical trial evaluating the safety and therapeutic efficacy of CD24Fc in severe COVID-19 patients
$1,000,000Pan Zheng · Oncoimmune, Inc. · R44 · FY2020 · CA
SQSTM1/p62-targeted Small Molecules for Multiple Myeloma Disease
$1,000,000James Lee · Id4pharma, Llc · R44 · FY2018 · CA
Role of Inter-alpha Inhibitors in Anthrax Intoxication
$1,000,000Steven M. Opal · Prothera Biologics, Llc · R42 · FY2010 · AI
AIVIS: Next Generation Vigilant Information Seeking Artificial Intelligence-based Clinical Decision Support for Sepsis
$1,000,000Christopher Josef · Clairyon, Inc. · R42 · FY2024 · AI
Human NeuromuscularJunction Platform to Evaluate Botulinum Toxin Potency
$1,000,000James F Kronauge · Hesperos, Llc · U44 · FY2024 · TR
eNamptorTM: A Humanized mAb To Reduce the Severity of Radiation Pneumonitis and Fibrosis
$1,000,000Joe G. N. Garcia · Aqualung Therapeutics Corp. · R42 · FY2022 · HL
Clinical Development of a Therapeutic Agent for COPD
$1,000,000Indu Parikh · Biomarck Pharmaceuticals, Ltd · R44 · FY2014 · HL
Simultaneous pharmacological profiling of oncogenic gene fusion proteins in cancer
$1,000,000Alexander Federation · Talus Bioscience, Inc. · R44 · FY2023 · CA
KL4 Surfactant to Mitigate Radiation-Induced Lung Injury
$999,999Robert Segal · Discovery Laboratories, Inc. · R44 · FY2014 · AI
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy
$999,999Robert Paul Myers · Orsobio, Inc. · R44 · FY2023 · DK
Chronic Kidney Disease in Children (CKiD)
$999,999Bradley Alan Warady · Children'S Mercy Hosp (Kansas City, Mo) · U01 · FY2008 · DK
Enabling Technology to Prepare Ultrapure Dialysate in Dialysis Clinics
$999,999Mohamed E Labib · Novaflux Technologies, Inc. · R44 · FY2013 · DK
Enabling Technology to Prepare Ultrapure Dialysate in Dialysis Clinics
$999,999Mohamed E Labib · Novaflux Technologies, Inc. · R44 · FY2012 · DK
TLC-1235, a controlled-release mitochondrial protonophore (CRMP), for the reversal of insulin resistance in patients with severe lipodystrophy
$999,999Robert Paul Myers · Orsobio, Inc. · R44 · FY2024 · DK
Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD
$999,998Thomas F Conway · Therapyx, Inc. · R44 · FY2011 · AI
Delivery of Nanoencapsulated TGFbeta and ATRA for the Treatment of IBD
$999,998Thomas F Conway · Therapyx, Inc. · R44 · FY2012 · AI